Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: In combination with the International Prognostic Index

Journal of Cancer Research and Clinical Oncology

Volumn 131, Issue 2, 2005, Pages 73-79

  Goto, Hideko ^a   Tsurumi, Hisashi ^a   Takemura, Masao ^a   Ino Shimomura, Yoriko ^a   Kasahara, Senji ^a   Sawada, Michio ^a   Yamada, Toshiki ^a   Hara, Takeshi ^a   Fukuno, Kenji ^a   Goto, Naoe ^a   Okuno, Masataka ^a   Takami, Tsuyoshi ^a   Seishima, Mitsuru ^a   Moriwaki, Hisataka ^a  

^a GIFU UNIVERSITY   (Japan)

Author keywords

International Prognostic Index (IPI); Non Hodgkin's lymphoma; Prognostic factor; Soluble interleukin 2 receptor (sIL 2R)

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; INTERLEUKIN 2 RECEPTOR; PIRARUBICIN; PREDNISONE; VINCRISTINE;

ADULT; ARTICLE; B CELL LYMPHOMA; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CHEMOTHERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NONHODGKIN LYMPHOMA; OUTCOMES RESEARCH; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SURVIVAL RATE; TIME SERIES ANALYSIS;

AGE FACTORS; AGED; FEMALE; HUMANS; LYMPHOMA, LARGE-CELL, DIFFUSE; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, INTERLEUKIN-2; RISK FACTORS; SOLUBILITY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 19944432777     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-004-0600-9     Document Type: Article

References (33)

1. Adida C, Haioun C, Gaulard P, Lepage E, Morel P, Briere J, Dombret H, Reyes F, Diebold J, Gisselbrecht C, Salles G, Altieri DC, Molina TJ (2000) Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 96:1921-1925
2. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson Jr J, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511
3. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M (1971) Report of the committee on Hodgkin's disease staging classification. Cancer Res 31:1860-1861
4. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Kippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an International Workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 17:1244-1253
5. Cox DR (1972) Regression models and life-tables (with discussions). J R Stat Soc (Series B) 34:187-220
6. Haioun C, Lepage E, Gisselbrecht C, Bastion Y, Coiffier B, Brice P, Bosly A, Dupriez B, Nouvel C, Tilly H, Lederlin P, Biron P, Briere J, Gaulard P, Reyes F for the Group d'Etude des Lymphomes de l'Adulte (1997) Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. J Clin Oncol 15:1131-1137
7. Hara T, Tsurumi H, Takemura M, Goto H, Yamada T, Sawada M, Takahashi T, Moriwaki H (2000) Serum-soluble Fas level determines clinical symptoms and outcome of patients with aggressive non-Hodgkin's lymphoma. Am J Hematol 64:257-261
8. Ichikawa A, Kinoshita T, Watanabe T, Kato H, Nagai H, Tsushita K, Saito H, Hotta T (1997) Mutation of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 337:529-534
9. The International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994
10. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds (2001) World health organization classification of tumors, pathology and genetics tumors of haematopoietic and lymphoid tissues. IARC, Lyon, 109-236
11. Kaplan EL, Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
12. Kitamura K, Takaku F (1990) Pirarubicin, a novel derivative of doxorubicin. THP-COP therapy for non-Hodgkin's lymphoma in the elderly. Am J Clin Oncol 13 [Suppl 1]:S15-S19
13. Kono N, Kanda Y, Yamamoto R, Chizuka A, Suguro M, Hamaki T, Arai C, Matsuyama T, Takezako N, Miwa A, Togawa A (2000) Prognostic significance of serum soluble interleukin-2 receptor level in non-Hodgkin's lymphoma: a single center study in Japan. Leuk Lymphoma 37:151-156
14. Miller AA, Salewski E (1994) Prospects for pirarubicin. Med Pediatr Oncol 22:261-268
15. Nicolaides C, Dimou S, Pavlidis N (1998) Prognostic factors in aggressive non-Hodgkin's lymphomas. Oncologist 3:189-197
16. Niitsu N, Okabe-Kado J, Kasukabe T, Yamamoto-Yamaguchi Y, Umeda M, Honma Y (1999) Prognostic implications of the differentiation inhibitory factor nm23-H1 protein in the plasma of aggressive non-Hodgkin's lymphoma. Blood 94:3541-3550
17. Niitsu N, Iijima K, Chizuka A (2001) A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma. Eur J Haematol 66:24-30
18. The non-Hodgkin's lymphoma pathologic classification project (1982) National Cancer Institute-sponsored study of classifications of non-Hodgkin's lymphomas. Summary and description of a working formulation for clinical usage. Cancer 49:2112-2135
19. Ogata K, Yokose N, An E, Kamikubo K, Tamura H, Dan K, Sakamaki H, Onozawa Y, Hamaguchi H, Nomura T (1996) Plasma soluble interleukin-2 receptor level in patients with primary myelodysplastic syndrome: a relationship with disease subtype and clinical outcome. Brit J Haematol 93:45-52
20. Preti HA, Cabanillas F, Talpaz M, Tucker SL, Seymour JF, Kurzrock R (1997) Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. Ann Intern Med 127:186-194
21. Rubin LA, Kurman CC, Fritz ME, Biddison WE, Boutin B, Yarchoan R, Nelson DL (1985) Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol 135:3172-3177
22. Rubin LA, Nelson DL (1990) The soluble interleukin-2 receptor: biology, function, and clinical application. Ann Intern Med 113:619-627
23. Salven P, Teerenhovi L, Joensuu H (1999) A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma. Blood 94:3334-3339
24. Sasaki K, Niitsu N (2000) Elevated serum levels of soluble CD44 variant 6 are correlated with shorter survival in aggressive non-Hodgkin's lymphoma. Eur J Haematol 65:195-202
25. Sawada M, Tsurumi H, Yamada T, Hara T, Fukuno K, Goto H, Shimizu M, Kasahara S, Yoshikawa T, Kanemura N, Oyama M, Takami T, Moriwaki H (2002) A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin's lymphoma who previously received CHOP therapy as first-line chemotherapy. Eur J Haematol 68:354-361
26. Semenzato G, Foa R, Agostini C, Zambello R, Trentin L, Vinante F, Benedetti F, Chilosi M, Pizzolo G (1987) High serum levels of soluble interleukin-2 receptor in patients with B chronic lymphocytic leukemia. Blood 70:396-400
27. Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler M, Montserrat E, Radford JA, Salles G, Schmitz N, Symann M, Armitage JO, Philip T, Coiffier B (1999) International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphoma: Report of the July. J Clin Oncol 17:423-429
28. Stasi R, Zinzani PL, Galieni P, Lauta VM, Damasio E, Dispensa E, Dammacco F, Papa G, Tura S (1994) Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin's lymphoma. Brit J Haematol 88:770-777
29. Takagi T, Oguro M (1987) (2″-R)-4′-o- Tetrahydropyranyladriamycin, a new anthracyclin derivative; its effectiveness in lymphoid malignancies. Cancer Chemother Pharmacol 20:151-154
30. Tsurumi H, Yamada T, Sawada M, Kasahara S, Kanemura N, Kojima Y, Fukuno K, Hara T, Saio M, Takahashi T, Oyama M, Ozawa K, Takami T, Moriwaki H (2004) Biweekly CHOP or biweekly THP-COP regimens in the treatment of aggressive non-Hodgkin's lymphoma: a comparison of doxorubicin and pirarubicin: a randomized phase II study. J Cancer Res Clin Oncol 130:107-113
31. Viviani S, Camerini E, Bonfante V, Santoro A, Balzarotti M, Fornier M, Devizzi L, Verderio P, Valagussa P, Bonadonna G (1998) Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications. Brit J Cancer 77: 992-997
32. Wagner DK, Kiwanuka J, Edwards BK, Rubin LA, Nelson DL, Magrath IT (1987) Soluble interleukin-2 receptor levels in patients with undifferentiated and lymphoblastic lymphomas: correlation with survival. J Clin Oncol 5:1262-1274
33. Yasuda N, Lai PK, Ip SH, Kung PC, Hinuma Y, Matsuoka M, Hattori T, Takatsuki K, Purtilo DT (1988) Soluble interleukin-2 receptors in sera of Japanese patients with adult T cell leukemia mark activity of disease. Blood 71:1021-1026